An observational study in Glycogen Storage Disease Type II, sponsored by Sanofi. Completed at 15 sites in 9 countries. Open to participants aged 0 Days to 6 Months. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by Sanofi · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies in Glycogen Storage Disease Type II by Sanofi — 4 open to participants now, 7 under way, 1 of them phase 3. Glycogen Storage Disease Type II · Sanofi.
Among the 41 studies in Glycogen Storage Disease Type II by Sanofi, this one is the 8th largest by enrollment of the 10 observational ones that give a count, is one of 4 that started in 2021, is one of 10 observational ones, and was the 36th registered.
162 studies on the registry are indexed under Glycogen Storage Disease Type II; 34 are open to participants now.
Browse Glycogen Storage Disease Type II studies →4 of the 41 studies in Glycogen Storage Disease Type II by Sanofi are open now, in 12 countries. Recruiting first, the newest first:
Genzyme, a Sanofi Company · Sites in China
Ages up to 17
Sanofi · Sites in United States
Women only
Genzyme, a Sanofi Company · Sites in United States, Australia, Belgium and 6 more countries
Women only
Genzyme, a Sanofi Company · Sites in United States, Argentina, Australia and 41 more countries
By country, each count listing its studies:
Of the 23 Glycogen Storage Disease Type II studies recruiting now, 16 (70%) set no upper age limit and 6 (26%) stop at 75 or younger; 15 take children under 18; none take healthy volunteers.
This study: 0 Days to 6 Months · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 10 · Phase 3 6 · Phase 4 13
First in 2001; this study’s year is marked. 4 started in 2021.
This study's enrollment of 9 is below the median of 50 across 64 observational studies indexed under Glycogen Storage Disease Type II.
Median enrollment 16 across the 29 interventional studies, 59 across the 10 observational. Of the 32 that completed or were terminated, 12 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
Sanofi is the lead sponsor of 1,560 studies on the registry; 90 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
1 of the studies in Glycogen Storage Disease Type II by Sanofi that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05164055Genzyme, a Sanofi CompanyAvalglucosidase Alfa French Post-trial Access for Participants With Pompe Disease (PTA Avalglucosidase) | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 41 studies in Glycogen Storage Disease Type II by Sanofi, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Primary Objective:
To describe the effect of routine practice with alglucosidase alfa in patients with IOPD ≤6 months of age, on invasive ventilation-free survival after 52 weeks of treatment.
Secondary Objectives:
The planned duration of observation for each participant will be 104 weeks after enrollment, to determine secondary outcomes at 18 months (approximately 78 weeks) of age.
Confirmly diagnosed IOPD patients 6 months or less of age (corrected for gestational age if needed), treated or planned to be treated with alglucosidase alfa, at the time of study inclusion.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants must have cardiomyopathy at the time of diagnosis (LVMI equivalent to mean age-specific LVMI):
Exclusion Criteria:
Participants with respiratory insufficiency, defined as:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Alglucosidase alfa GZ419829
Pharmaceutical form: Lyophilized powder for solution Route of administration: intravenous
Also known as: Myozyme
Proportion of participants alive and free of invasive ventilation at Week 52 of treatment
Time frame: Week 52
Proportion of participants alive and free of invasive ventilation at 12 and 18 months of age
Time frame: at 12 and 18 months of age
Proportion of participants alive at Week 52 of treatment
Time frame: Week 52
Proportion of participants alive at 12 months and 18 months of age
Time frame: at 12 and 18 months of age
Proportion of participants free of ventilator use and free of supplemental oxygen use at Week 52
Time frame: Week 52
Change from baseline to Week 52 in LVM Z score
Time frame: from baseline to Week 52
Change from baseline to Week 52 in AIMS score
Time frame: from baseline to Week 52
Change from baseline to Week 52 in body length Z-scores
Time frame: from baseline to Week 52
Change from baseline to Week 52 in body weight Z-scores
Time frame: from baseline to Week 52
Change from baseline to Week 52 in head circumference Z-scores
Time frame: from baseline to Week 52
Change from baseline to Week 52 in body length percentiles
Time frame: from baseline to Week 52
Change from baseline to Week 52 in body weight percentiles
Time frame: from baseline to Week 52
Change from baseline to Week 52 in head circumference percentiles
Time frame: from baseline to Week 52
Change from baseline to Week 52 in urinary Hex4
Time frame: from baseline to Week 52
Number of participants experiencing at least 1 treatment-emergent adverse events (TEAE), including infusion-associated reactions (IAR)
Time frame: From inclusion for 104 weeks
Number of participants with abnormalities in physical examinations
Time frame: From inclusion for 104 weeks
Number of participants with abnormalities in clinical laboratory results
Time frame: From inclusion for 104 weeks
Number of participants with abnormalities in vital signs measurements
Time frame: From inclusion for 104 weeks
Number of participants with abnormalities in 12-lead electrocardiogram (ECG)
Time frame: From inclusion for 104 weeks
Incidence of treatment-emergent antidrug antibodies (ADA)
Time frame: From inclusion for 104 weeks
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
No publications or documents are linked to this record.
Ran from Jun 2021 to primary completion in Oct 2026, 64 months.
Of 29 observational studies under Glycogen Storage Disease Type II, half reached primary completion within 73 months of starting (the median), counting those still running; a quarter within 33. This study's 64 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Glycogen Storage Disease Type II →